OAKVILLE, ON, May 19, 2015 /CNW/ - ENTYVIO™ (vedolizumab), a new biologic treatment to treat ulcerative colitis (UC), one of the two most common types of inflammatory bowel disease, is now ...

Fresenius Kabi has entered a global licensing agreement for the commercialisation of Polpharma Biologics’s vedolizumab ...

ENTYVIO™ was first approved by Health Canada last year for the treatment of ulcerative colitis (UC), the second most common form of inflammatory bowel disease. i ENTYVIO™ is the first and only ...

Ulcerative Colitis Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical trials, Medication, Therapies, Prevalence and Companies by DelveInsight GetNews - TGAM - GetNews - Thu Mar 27, 6:12AM CDT ...

Biologics target the inflammatory activity of a person's own immune system, setting them apart from other medications for ulcerative colitis, Dr. Tsynman says.

The VARSITY study, a first-of-its-kind comparison of two biologics in ulcerative colitis, provides valuable information that can help inform treatment decisions, while also increasing our ...

More people showed a response to treatment with Omvoh versus a placebo (no medicine) for ulcerative colitis at 12 weeks and at 52 weeks. More people taking Omvoh had improvements in symptoms and ...

Crohn's disease and ulcerative colitis, the two main types of inflammatory bowel disease (IBD), are lifelong debilitating medical conditions with no cures. One in 150 Canadians has Crohn's or ...

Future perspectives in ulcerative colitis research Ongoing research into ulcerative colitis continues to uncover new treatment options, therapies, and ways to improve patient outcomes.

TAKEAWAY: Among 11,992 adult patients newly initiating biologic therapy (median age, 47 years; 52.7% women), 1293 (10.8%) underwent a biologic switch during a minimum follow-up of 90 days.